Loading
A phase 2 trial of gemcitabine + nab-paclitaxel, gemcitabine, capecitabine and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.
Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC is a phase 2, interventional study registered as NCT07833241 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 56 participants, started 2026-09-01 and due to reach its primary completion in 2028-09-01. Interventions recorded: Surufatinib Plus Iparomlimab and Tuvonralimab and AG Chemotherapy; Gemcitabine plus Capecitabine; Modified FOLFIRINOX. Conditions listed: Borderline Resectable Pancreatic Cancer; High-Risk Resectable Pancreatic Cancer. Primary outcome: 12-month Event Free Survival (EFS) rate. Pancreatic eligibility wording from the registry: "* Patients with high-risk resectable or borderline resectable pancreatic adenocarcinoma confirmed by histopathology or cytology". Sites: China. No results are recorded here; the registry entry is the source.
Shares Gemcitabine + nab-paclitaxel, FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.